- Home
- FGEN vs RNXT Comparison
FGEN vs RNXT Comparison
Compare FGEN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- RNXT
- Stock Information
- Founded
- FGEN 1993
- RNXT 2012
- Country
- FGEN United States
- RNXT United States
- Employees
- FGEN N/A
- RNXT N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- RNXT Health Care
- Exchange
- FGEN Nasdaq
- RNXT Nasdaq
- Market Cap
- FGEN 38.4M
- RNXT 44.6M
- IPO Year
- FGEN 2014
- RNXT 2021
- Fundamental
- Price
- FGEN $12.03
- RNXT $1.28
- Analyst Decision
- FGEN Strong Buy
- RNXT Strong Buy
- Analyst Count
- FGEN 2
- RNXT 2
- Target Price
- FGEN $146.50
- RNXT $7.50
- AVG Volume (30 Days)
- FGEN 52.5K
- RNXT 594.5K
- Earning Date
- FGEN 11-11-2025
- RNXT 11-12-2025
- Dividend Yield
- FGEN N/A
- RNXT N/A
- EPS Growth
- FGEN N/A
- RNXT N/A
- EPS
- FGEN N/A
- RNXT N/A
- Revenue
- FGEN $7,346,000.00
- RNXT $662,000.00
- Revenue This Year
- FGEN N/A
- RNXT $2,988.37
- Revenue Next Year
- FGEN N/A
- RNXT $300.60
- P/E Ratio
- FGEN N/A
- RNXT N/A
- Revenue Growth
- FGEN N/A
- RNXT N/A
- 52 Week Low
- FGEN $4.50
- RNXT $0.75
- 52 Week High
- FGEN $21.94
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- FGEN 61.59
- RNXT 61.50
- Support Level
- FGEN $11.12
- RNXT $1.06
- Resistance Level
- FGEN $12.53
- RNXT $1.27
- Average True Range (ATR)
- FGEN 0.85
- RNXT 0.10
- MACD
- FGEN -0.05
- RNXT 0.04
- Stochastic Oscillator
- FGEN 75.11
- RNXT 69.64
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.